CYP2D6 metabolizes codeine to morphine, the active analgesic metabolite. Variation in brain CYP2D6 activity may affect brain morphine levels after codeine administration and thereby influence analgesia. We investigate the effect of inhibiting brain CYP2D on codeine-induced analgesia. METHODS: Rats received intracerebroventricular (i.c.v.) injections of CYP2D inhibitors or vehicle controls. Rats were then given subcutaneous codeine injections and analgesia was measured with the tail-flick test. Morphine and codeine concentrations in brain and plasma were measured. CYP2D activity in brain and liver were assessed in vitro. RESULTS: Compared to vehicle treatment, i.c.v. inhibitor treatments resulted in lower codeine-induced analgesia, lower morphine levels in brain but not in plasma after codeine injections, and lower CYP2D activity in brain membranes but not in liver microsomes. CONCLUSIONS: Inhibiting brain CYP2D reduces codeine’s metabolism to morphine, resulting in less analgesia. Variation in brain CYP2D6 activity may influence response to codeine and other CYP2D6 substrates.

CYP2D6 metabolizes codeine to morphine, the active analgesic metabolite. Variation in brain CYP2D6 activity may affect brain morphine levels after codeine administration and thereby influence analgesia. We investigate the effect of inhibiting brain CYP2D on codeine-induced analgesia. METHODS: Rats received intracerebroventricular (i.c.v.) injections of CYP2D inhibitors or vehicle controls. Rats were then given subcutaneous codeine injections and analgesia was measured with the tail-flick test. Morphine and codeine concentrations in brain and plasma were measured. CYP2D activity in brain and liver were assessed in vitro. RESULTS: Compared to vehicle treatment, i.c.v. inhibitor treatments resulted in lower codeine-induced analgesia, lower morphine levels in brain but not in plasma after codeine injections, and lower CYP2D activity in brain membranes but not in liver microsomes. CONCLUSIONS: Inhibiting brain CYP2D reduces codeine’s metabolism to morphine, resulting in less analgesia. Variation in brain CYP2D6 activity may influence response to codeine and other CYP2D6 substrates.

An ultra-low dose of a drug is approximately 1000-fold lower than the dose range traditionally used to induce a therapeutic effect. The purpose of the present thesis was to broaden the knowledge of the ultra-low dose effect, that was previously identified in the opioid receptor system, by looking at whether opioids and cannabinoids interact at the ultra-low dose level, whether cannabinoid receptors themselves demonstrate the ultra-low dose antagonist effect, and whether the opioid ultra-low dose effect is maintained in a model of persistent, unavoidable pain. For experiment 1, separate groups of Long Evans rats were tested for antinociception following an injection of vehicle, the cannabinoid agonist WIN 55 212-2 (WIN), the opioid antagonist naltrexone (an ultra-low or a high dose), or a combination of WIN and naltrexone doses. Ultra-low dose naltrexone elevated WIN-induced tail flick thresholds without extending its duration of action. In experiment 2, antinociception was tested in rats following either acute or sub-chronic (7 days) injections of vehicle, WIN, ultra-low doses of the CB1 receptor antagonist rimonabant (SR 141716), or a combination of WIN and ultra-low dose rimonabant. Following the chronic experiment, striatal tissue was rapidly extracted and subjected to co-immunoprecipitation to analyse CB1 receptor coupling to G-protein subtypes. Ultra-low dose rimonabant extended the duration of WIN-induced antinociception, and attenuated the development of WIN-induced tolerance. Animals chronically treated with WIN alone had CB1 receptors predominately coupling to Gs proteins, whereas all other groups had CB1 receptors predominately coupling to Gi proteins. For experiment 3, all animals were subjected to the formalin test following either acute or sub-chronic injections of vehicle, the opiate morphine, ultra-low doses naltrexone, or a combination of morphine and ultra-low dose naltrexone. Ultra-low dose naltrexone had no significant effect on morphine-induced pain ratings in either the acute, or sub-chronic drug treatments. This thesis provides evidence that the ultra-low dose effect, including the agonist-induced G-protein coupling switch, extends to another receptor type. This effect may, therefore, be part of a generalized principle that applies to many G-protein coupled receptors. / Thesis (Ph.D, Psychology) -- Queen's University, 2007-11-05 09:31:30.162 / A portion of this research was supported by a Canadian Institutes of Health Research (CIHR) Proof of Principle Grant to M.C. Olmstead and J.J. Paquette.

Bases: A antinocicepção induzida por substâncias doces tem sido largamente estudada. Contudo, a investigação dos neurotransmissores envolvidos nesse processo antinociceptivo ainda carece de mais estudos, pois é de extrema importância entender o envolvimento desses neurotransmissores no sistema neural que controla este tipo de antinocicepção. Objetivo: O objetivo deste estudo é clarificar o envolvimento dos sistemas opióide e serotoninérgico na antinocicepção induzida por substância doce. Método: O presente trabalho foi realizado em modelo animal (Rattus norvegicus, Rodentia, Muridae), objetivando investigar se a ingestão crônica de solução de sacarose é seguida de antinocicepção. A latência de retirada de cauda após a aplicação de estímulo nocivo térmico foi medida antes e após esse tratamento no teste de retirada de cauda (provavelmente um reflexo espinal). Não houve diferenças estatisticamente significantes entre os valores de linha basal dos diferentes grupos e foi calculado um índice de analgesia da latência de retirada de cauda antes e depois do tratamento. O envolvimento de opióides endógenos e de serotonina neste processo antinociceptivo foi pesquisado com fármacos antagonistas específicos e não-específicos dos receptores opióides e serotoninérgicos. Resultados: O efeito analgésico da ingestão de sacarose depende da concentração da solução de sacarose e do tempo de duração do consumo da mesma. Naltrexona e metisergida diminuíram a antinocicepção induzida por substâncias doce (após 14 dias de ingestão da sacarose). Estes efeitos foram corroborados pela administração periférica de naloxonazina e cetanserina. Conclusões: Os resultados sugerem o envolvimento de opióides endógenos e serotonina no processo antinociceptivo atualmente estudado. Tudo apontando para a participação de receptores opióides µ1 e serotoninérgicos 5-HT2 na regulação central da antinocicepção induzida por substâncias doces. / Rationale: Sweet substance-induced antinociception has been widely studied, and the investigation of the neurotransmitters involved in the antinociceptive process is an important way for understanding the involvement of neural system controlling this kind of antinociception. Objective: The aim of this study is to investigate the involvement of opioid and serotonergic system in the sweet substance-induces antinociception. Methods: the present work was made in animal model (Rattus norvegicus, Rodentia, Muridae); with the aim of investigating if the chronic intake of sweet substance, such as sucrose, is followed by antinociception. Their tail withdrawal latencies in the tail-flick test (probably a spinal reflex) were measured before and immediately after this treatment. As there was not statistic significant differences between baseline values of different groups, an analgesia index was calculated from the withdrawal latencies before and after treatment. The involvement of endogenous opioid and serotonin in the antinociceptive process was investigated with specific and non-specific pharmacological antagonism on opioid and serotonergic receptors. Results: The analgesic effect of sucrose intake depends on the concentration of sucrose solution and on the time during which the solution is consumed. Naltrexone and methysergide decreased the sweet substance-induced antinociception (post 14 days of sucrose intake). These effects were corroborated by peripheral administration of naloxonazina and ketanserin. Conclusions: The present results suggest the involvement of endogenous opioids and serotonin in the antinociceptive process presently studied. µ1-opioid and 5-HT2 serotonergic receptors may be involved in the central regulation of the sweet substance-produced antinociception.

Bases: A antinocicepção induzida por substâncias doces tem sido largamente estudada. Contudo, a investigação dos neurotransmissores envolvidos nesse processo antinociceptivo ainda carece de mais estudos, pois é de extrema importância entender o envolvimento desses neurotransmissores no sistema neural que controla este tipo de antinocicepção. Objetivo: O objetivo deste estudo é clarificar o envolvimento dos sistemas opióide e serotoninérgico na antinocicepção induzida por substância doce. Método: O presente trabalho foi realizado em modelo animal (Rattus norvegicus, Rodentia, Muridae), objetivando investigar se a ingestão crônica de solução de sacarose é seguida de antinocicepção. A latência de retirada de cauda após a aplicação de estímulo nocivo térmico foi medida antes e após esse tratamento no teste de retirada de cauda (provavelmente um reflexo espinal). Não houve diferenças estatisticamente significantes entre os valores de linha basal dos diferentes grupos e foi calculado um índice de analgesia da latência de retirada de cauda antes e depois do tratamento. O envolvimento de opióides endógenos e de serotonina neste processo antinociceptivo foi pesquisado com fármacos antagonistas específicos e não-específicos dos receptores opióides e serotoninérgicos. Resultados: O efeito analgésico da ingestão de sacarose depende da concentração da solução de sacarose e do tempo de duração do consumo da mesma. Naltrexona e metisergida diminuíram a antinocicepção induzida por substâncias doce (após 14 dias de ingestão da sacarose). Estes efeitos foram corroborados pela administração periférica de naloxonazina e cetanserina. Conclusões: Os resultados sugerem o envolvimento de opióides endógenos e serotonina no processo antinociceptivo atualmente estudado. Tudo apontando para a participação de receptores opióides µ1 e serotoninérgicos 5-HT2 na regulação central da antinocicepção induzida por substâncias doces. / Rationale: Sweet substance-induced antinociception has been widely studied, and the investigation of the neurotransmitters involved in the antinociceptive process is an important way for understanding the involvement of neural system controlling this kind of antinociception. Objective: The aim of this study is to investigate the involvement of opioid and serotonergic system in the sweet substance-induces antinociception. Methods: the present work was made in animal model (Rattus norvegicus, Rodentia, Muridae); with the aim of investigating if the chronic intake of sweet substance, such as sucrose, is followed by antinociception. Their tail withdrawal latencies in the tail-flick test (probably a spinal reflex) were measured before and immediately after this treatment. As there was not statistic significant differences between baseline values of different groups, an analgesia index was calculated from the withdrawal latencies before and after treatment. The involvement of endogenous opioid and serotonin in the antinociceptive process was investigated with specific and non-specific pharmacological antagonism on opioid and serotonergic receptors. Results: The analgesic effect of sucrose intake depends on the concentration of sucrose solution and on the time during which the solution is consumed. Naltrexone and methysergide decreased the sweet substance-induced antinociception (post 14 days of sucrose intake). These effects were corroborated by peripheral administration of naloxonazina and ketanserin. Conclusions: The present results suggest the involvement of endogenous opioids and serotonin in the antinociceptive process presently studied. µ1-opioid and 5-HT2 serotonergic receptors may be involved in the central regulation of the sweet substance-produced antinociception.

Made available in DSpace on 2016-06-02T19:22:05Z (GMT). No. of bitstreams: 1 3116.pdf: 11974848 bytes, checksum: d69698c04f669985473e9e441c532444 (MD5) Previous issue date: 2009-12-11 / Universidade Federal de Sao Carlos / In innate or learned threatening situations, animals display a set of defensive behaviors specie-specific such as autonomic alterations, flight, fight and antinociception. Exposure of mice to open elevated plus-maze (oEPM: four open arms), an aversive situation, elicits antinociception of high magnitude. However, mechanisms involved in this kind of antinociception are not clear yet. This study investigated whether antinociception induced by exposure to an oEPM shows cross-tolerance with morphine (Exp. I and II); is attenuated by repetead exposure to the oEPM (Exp. III); is blocked by systemic treatment with naltrexone (Exp. IV); is prevented by adrenalectomy (Exp. V); persists after animal removal from the oEPM and if there are sex-related differences in this factor (Exp. VI); is mediated by CB1 cannabinoid receptor (Exp. VII). Rats were daily treated with morphine (M, 5 mg/kg, i.p.) or distilled water (DW) for 5 consecutive days (antinociceptive tolerance assessed by the tailflick test). Next day, rats received formalin 2.5% injection (50 μL) into the right hind paw and, after first phase of formalin test, they were treated with M or DW. 25 minutes after formalin injection into the paw, time spent licking the injected paw was recorded for 10 minutes (Exp. 1). Similar procedure was followed in the Experiment II, except that time spent licking the paw was recorded during exposure to the oEPM or enclosed EPM (eEPM: four arms enclosed) in undrugged rats. In Experiment III, nociception was evaluated in rats submitted to 1, 2, 3, 4 or 6 exposures to either eEPM or oEPM (formalin was injected only during the last exposure). Experiment IV investigated the effects of naltrexone (0 and 2.5 mg/kg; s.c.) on nociception during eEPM or oEPM exposure. Nociception was also assessed during the eEPM or oEPM exposure in sham and adrenalectomized rats (exp. V). In experiment VII, rats were treated with vehicle (DMSO 60%) or AM251 (1 mg/kg, i.p., CB1 receptor antagonist). Fifteen minutes later, animals received formalin injection into the paw and, 25 minutes after, they were exposed to the eEPM or oEPM. In experiment VI, male and female rats were exposed to eEPM or oEPM (with no noxious stimulus during exposure) and imediately after they were tested on the hot plate test (52.4 °C). Results showed that antinociception induced by oEPM does not display cross-tolerance to morphine; was not altered for at least 6 exposures to the maze; failed to be reversed by naltrexone; was not prevented by adrenalectomy and was not blocked by AM251. In addition, this antinociception does not persist after animal removal of the apparatus, by contrast, it occurs a hyperalgesia (as assessed by hot plate test), a response that does not depend on sex-related differences. Results suggest that antinociception induced by oEPM: is not mediated by opioid system or CB1 cannabinoid receptors and it is not sensitive to corticosterone. Furthermore, animal removal of aversive environment alters nociceptive response from antinociception to hyperalgesia, a phenomenon that is independent of the gender. / Em situações ameaçadoras de natureza inata ou aprendida, animais exibem um conjunto de comportamentos defensivos espécie-específicos, tais como alterações autonômicas, fuga, luta e antinocicepção. A exposição de camundongos ao labirinto em cruz elevado aberto (LCEa: quatro braços abertos), uma situação aversiva, induz antinocicepção de alta magnitude. Todavia, os mecansimos envolvidos em tal antinocicepção ainda não estão elucidados. O presente estudo investigou se a antinocicepção induzida por exposição ao LCEa: mostra tolerância cruzada a morfina (experimentos I e II); é atenuada por exposição repetida ao LCEa (experimento III); é revertida por tratamento sistêmico com naltrexona (experimento IV); é impedida por adrenalectomia (experimento V); persiste após remoção do animal do LCEa e se há diferenças relacionadas ao sexo neste fator (experimento VI); é mediada pelo receptor canabinóide, CB1 (experimento VII). Ratos foram diariamente tratados com morfina (M, 5 mg/Kg, i.p.) ou água destilada (AD) por 5 dias consecutivos (tolerância antinociceptiva avaliada pelo teste de retirada da cauda). No dia seguinte, os ratos receberam injeção de formalina 2,5% (50L) na pata traseira direita e, após a primeira fase do teste de formalina, foram tratados com M ou AD. Vinte e cinco minutos após injeção de formalina na pata, o tempo de lambidas na pata foi registrado por 10 minutos (experimento I). Procedimento semelhante foi utilizado no experimento II, exceto que o tempo de lambidas na pata foi registrado durante exposição ao LCEa ou LCE fechado (LCEf: quatro braços fechados). No experimento III, nocicepção foi avaliada em ratos submetidos a 1, 2, 3, 4 ou 6 exposições ao LCEf ou LCEa (formalina injetada somente durante a última exposição). O experimento IV investigou os efeitos de naltrexona (2,5 mg/kg; s.c.) sobre a nocicepção durante exposição ao LCEf ou LCEa. A nocicepção também foi avaliada durante exposição ao LCEf ou LCEa em ratos sham operados e adrenalectomizados (experimento V). No experimento VII, os ratos foram tratados com veículo (DMSO 60%) ou AM251 (1 mg/kg, i.p., antagonista CB1). Quinze minutos após, os animais receberam formalina na pata e, após 25 minutos, foram expostos ao LCEf ou LCEa. Já no experimento VI, ratos machos e fêmeas foram expostos ao LCEf ou LCEa, sem nenhum estímulo nociceptivo aplicado durante exposição e, imediatamente após, foram testados no teste da placa quente (52,4 °C). Os resultados mostraram que a antinocicepção induzida pelo LCEa não exibe tolerância cruzada a morfina; não foi alterada por ao menos 6 exposições ao labirinto; mostrou-se insensível à naltrexona; não foi impedida por adrenalectomia e não foi bloqueada por AM251. Ainda, tal antinocicepção não perdura após remoção dos animais do aparelho, pelo contrário, ocorre uma hiperalgesia (conforme avaliado pelo teste de placa quente), uma resposta que independe de diferenças relacionadas ao sexo. Os resultados sugerem que a antinocicepção induzida pelo LCEa: não é mediada por sistema opióide ou receptores canabinóides CB1 e não é sensível a corticosterona. Além disso, a retirada dos animais do ambiente aversivo altera a resposta nociceptiva de antinocicepção para hiperalgesia, um fenômeno que independe do gênero.